Polarean (AIM: POLX), a commercial-stage medical device
leader in advanced magnetic resonance imaging (MRI) of the lungs,
has been selected as one of the featured companies and a poster
presenter at the American Thoracic Society’s (ATS) 2024 Respiratory
Innovation Summit (RIS), a testament to the value of our XENOVIEW
technology seen across lung clinicians and pulmonary drug
developers. The summit is scheduled to take place on May 17th-18th
in San Diego, CA, at the Manchester Grand Hyatt San Diego.
The Respiratory Innovation Summit, a premier
event in the field of pulmonary medicine, unites innovators,
investors, clinicians, and advocacy groups. The meeting
historically attracts more than 275 global leaders representing all
facets of the respiratory industry, including start-ups, venture
capital, government, academia, and clinicians.
After the dynamic discussions of the Respiratory Innovation
Summit, Polarean eagerly anticipates further collaboration within
the pulmonary medicine community at the 2024 ATS International
Conference, held from May 19th to 22nd. Visit booth #2813 to
engage directly with our executive team, including Christopher von
Jako, PhD, Chief Executive Officer; Alex Dusek, Chief Commercial
Officer; and Kiarash Emami, PhD, VP of Technology &
Applications. Discover firsthand how Polarean strives to
revolutionize pulmonary medicine through direct visualization of
lung ventilation as we share detailed insights, forge valuable
connections, and collaborate to shape the future of lung
imaging.
This year, the breadth of Xenon MRI research and the number of
displays outpaced all previous years, with 33 presentations from 10
different sites and multiple categories, including asthma,
bronchopulmonary dysplasia, COPD, COVID-19, cystic fibrosis,
hematopoietic stem cell transplant, lung cancer resection,
radiation-induced lung injury, pulmonary arterial hypertension, and
thoracic insufficiency syndrome. Christopher von
Jako, PhD, CEO of Polarean, said: “The Respiratory
Innovation Summit and the ATS annual conference serve as invaluable
venues to spotlight our Xenon MRI platform, especially to those
enthusiastic about fostering collaborative partnerships. These
events provide an unparalleled opportunity to elevate awareness of
our technology among clinicians, regulators, investors, and
potential pharmaceutical industry partners. As we strive to advance
our commercialization strategy, the increase in Xenon MRI posters
and presentations marks significant strides in amplifying
understanding and enthusiasm for Xenon MRI and the spectrum of
therapeutic disciplines that could benefit from our
technology.”
See the listing below for details on the presentation title,
abstract number, session time, and location.
XENOVIEW IMPORTANT SAFETY INFORMATION
IndicationXENOVIEW™, prepared
from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent
indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients
aged 12 years and older.
Limitations of UseXENOVIEW has
not been evaluated for use with lung perfusion imaging.
CONTRAINDICATIONSNone.
Warnings and Precautions Risk
of Decreased Image Quality from Supplemental Oxygen: Supplemental
oxygen administered simultaneously with XENOVIEW inhalation can
cause degradation of image quality. For patients on supplemental
oxygen, withhold oxygen inhalation for two breaths prior to
XENOVIEW inhalation, and resume oxygen inhalation immediately
following the imaging breath hold.
Risk of Transient Hypoxia: Inhalation of an
anoxic gas such as XENOVIEW may cause transient hypoxemia in
susceptible patients. Monitor all patients for oxygen desaturation
and symptoms of hypoxemia and treat as clinically indicated.
Adverse Reactions Adverse
Reactions in Adult Patients: The adverse reactions (> one
patient) in efficacy trials were oropharyngeal pain, headache, and
dizziness. Adverse Reactions in Pediatric and Adolescent
Patients: In published literature in pediatric patients aged 6 to
18, transient adverse reactions were reported: blood oxygen
desaturation, heart rate elevation, numbness, tingling, dizziness,
and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient
increase in heart rate was reported following hyperpolarized xenon
Xe 129 administration. XENOVIEW is not approved for use in
pediatric patients less than 12 years of age.
Please see full prescribing information
at www.xenoview.net
About Polarean
(www.polarean.com)Polarean is a revenue-generating medical imaging
technology company revolutionizing pulmonary medicine through
direct visualization of lung function by introducing the power and
safety of MRI to the respiratory healthcare community. This
community is in desperate need of modern solutions to accurately
assess lung function. The Company strives to optimize lung health
and prevent avoidable loss by illuminating hidden disease,
addressing the global unmet medical needs of more than 500 million
patients worldwide suffering from chronic respiratory disease.
Polarean is a leader in the field of hyperpolarization science and
has successfully developed the first and only hyperpolarized Xenon
MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in
the United States. Polarean is dedicated to researching,
developing, and commercializing innovative imaging solutions with
its non-invasive and radiation-free pulmonary functional MRI
platform. This comprehensive drug-device platform encompasses the
proprietary Xenon gas blend, gas hyperpolarization system, as well
as software and accessories, facilitating fully integrated modern
respiratory imaging operations. Founded in 2012, with offices in
Durham, NC, and London, United Kingdom, Polarean is committed to
increasing global awareness of and broad access to its XENOVIEW MRI
technology platform. For the latest news and information about
Polarean, please visit www.polarean.com.
About The American Thoracic
Society (www.thoracic.org)The American Thoracic Society
(ATS) improves global health by advancing research, patient care,
and public health in pulmonary disease, critical illness, and sleep
disorders. Founded in 1905 to combat TB, the ATS has grown to
tackle asthma, COPD, lung cancer, sepsis, acute respiratory
distress, and sleep apnea, among other diseases.
|
ATS Abstract Title |
Presentation Date |
Abstract Number |
Session and Location |
|
Hyperpolarized 129Xe MRI: What Additional Information Does
It Provide? |
May 18, 20243:10 PM - 3:50 PM |
|
Session PG16 San Diego Convention Center, Room 6D
(UpperLevel) |
|
Quantifying the Impact of Cannabis Smoking in Lungs of
Young Adults Using CT and Xe MRI |
May 19, 2024 9:15 AM - 11:15 AM |
1014 |
Session A29San Diego Convention Center,
Room 6E (UpperLevel) |
|
Six-month Longitudinal Changes in129-XE and HRCT Imaging
Metrics Tend to Associate With On-study COPD
Exacerbations |
May 19, 20249:15 AM - 11:15 AM |
1017 |
Session A29 San Diego Convention Center, Room 6E
(UpperLevel) |
|
Advanced 4D Hyperpolarized Gas Imaging of Ventilation and
Dissolved Gas Biomarkers in COPD |
May 19, 20249:15 AM - 11:15 AM |
1016 |
Session A29San Diego Convention Center,
Room 6E (UpperLevel) |
|
3-month Change in Hyperpolarized Xe MRI Membrane Uptake
Predicts 6-month Change in Lung Function in Patients With
Idiopathic Pulmonary Fibrosis |
May 19, 202411:30 AM - 1:15 PM |
P862 |
Session A47San Diego Convention Center,
Area H (Hall H,Ground Level) |
|
Using Xenon MRI to Evaluate the Trajectories of Idiopathic
Pulmonary Fibrosis |
May 19, 2024 2:15 PM - 4:15 PM |
914 |
Session A104San Diego Convention Center,
Room 33A-C(Upper Level) |
|
Combining Hyperpolarized Xe MR Imagingand Spectroscopy to
Estimate Pulmonary Vascular Resistance |
May 19, 2024 3:39 PM - 3:51 PM |
|
Session A97San Diego Convention Center,
Room 6D (UpperLevel) |
|
Magnetic Resonance Imaging Ventilation Phenotypes of Severe
Asthma |
May 19, 2024 3:39 PM - 3:51 PM |
|
Session A99Marriott Marquis San Diego
Marina, PacificBallroom 24-26 (Ground Floor, North
Tower) |
|
Success and Feasibility of MultipleBreath Washout:
Prospective Multi-center Results From the Transpire
Study |
May 20, 2024 9:15 AM - 11:15 AM |
421 |
Session B25San Diego Convention Center,
Room 25A-C(Upper Level) |
|
Improved Quantification of Ventilation Heterogeneity in
Hyperpolarized Xenon MRI Using Physics-rooted Bias-field
Correction |
May 20, 2024 11:30 AM - 1:15 PM |
P170 |
Session B80-1San Diego Convention Center,
Area B (Hall A-B2,Ground Level) |
|
Addressing Healthy Aging Variations in Ventilation From
Childhood to Older Age Using Xenon MRI |
May 20, 2024 11:30 AM - 1:15 PM |
P171 |
Session B80-1San Diego Convention Center,
Area B (Hall A-B2,Ground Level) |
|
Assessing Radiation-induced Lung Injury Using a Chemical
Shift Imaging-based CSSR Technique |
May 20, 2024 11:30 AM - 1:15 PM |
P176 |
Session B80-1San Diego Convention Center,
Area B (Hall A-B2,Ground Level) |
|
Sex and Age-dependence of Xe MRI Cardiopulmonary
Oscillations in Healthy Volunteers |
May 20, 2024 11:30 AM - 1:15 PM |
P188 |
Session B80-1San Diego Convention Center,
Area B (Hall A-B2,Ground Level) |
|
Estimating Physiological Values of Membrane and Red Blood
Cell Conductance Using Xe Gas Exchange MRI |
May 20, 2024 11:30 AM - 1:15 PM |
P187 |
Session B80-1San Diego Convention Center,
Area B (Hall A-B2,Ground Level) |
|
Increased BMI Is Associated With Elevated Membrane Uptake
on Xe Gas Exchange MRI in Healthy Subjects |
May 20, 2024 11:30 AM - 1:15 PM |
P178 |
Session B80-1San Diego Convention Center,
Area B (Hall A-B2,Ground Level) |
|
Establishing a Standardized Healthy Reference Distribution
for Multi-site Xe Gas Exchange MRI Across Major Scanner
Platforms |
May 20, 2024 11:30 AM - 1:15 PM |
P172 |
Session B80-1San Diego Convention Center,
Area B (Hall A-B2,Ground Level) |
|
Quantifying Spatial Distribution of Ventilation Defects in
Lung Imaging With Hyperpolarized Xenon MRI |
May 20, 202411:30 AM - 1:15 PM |
P174 |
Session B80-1San Diego Convention Center,
Area B (Hall A-B2,Ground Level) |
|
Assessment of Gas Exchange WithHyperpolarized Xe MR Imaging
in Mild Asthmatics When Administered a Vasodilator |
May 20, 2024 11:30 AM - 1:15 PM |
P190 |
Session B80-1San Diego Convention Center,
Area B (Hall A-B2,Ground Level) |
|
129Xe MRI With Optimized Bias Field Correction to Assess
Ventilation Gradients in Individuals With Normal Lung
Function |
May 20, 2024 11:30 AM - 1:15 PM |
P701 |
Session B80-2 |
|
Research and Clinical Applications of Hyperpolarized 129Xe
MRI |
May 20, 2024 3:00 PM - 3:15 PM |
|
Session B91San Diego Convention Center,
Room 24A-C(Upper Level) |
|
Assessment of Obstructive and Restrictive Lung Disease Via
MRI in Bronchopulmonary Dysplasia Patients |
May 21, 2024 9:15 AM - 11:15 AM |
404 |
Session C29San Diego Convention Center,
Room 25A-C(Upper Level) |
|
Changes in Individual Ventilation Defects in Cystic
Fibrosis After Initiation of Modulator Therapy, in the Hypoint
Trial |
May 21, 2024 9:15 AM - 11:15 AM |
405 |
Session C29San Diego Convention Center,
Room 25A-C(Upper Level) |
|
Xe MRI and Oscillometry Evidence ofImproved Small Airways
Dysfunction After 6-weeks ICS/LABA/LAMA Therapy in Moderate
Asthma |
May 21, 2024 9:15 AM - 11:15 AM |
407 |
Session C29San Diego Convention Center,
Room 25A-C(Upper Level) |
|
Comparison of CT-based Measurements of Ventilation and
Perfusion to Ventilation and Gas Exchange Measurements From
Hyperpolarized Xe MRI |
May 21, 2024 9:15 AM - 11:15 AM |
410 |
Session C29San Diego Convention Center,
Room 25A-C(Upper Level) |
|
CT Mucus Score Predicts Response to 6-weeks ICS/LABA/LAMA
in Moderate Asthma |
May 21, 2024 9:15 AM - 11:15 AM |
413 |
Session C29San Diego Convention Center,
Room 25A-C(Upper Level) |
|
Xe MR Evidence of Abnormal Gas-exchange in Mild-moderate
and Severe Asthma |
May 21, 2024 9:15 AM - 11:15 AM |
418 |
Session C29San Diego Convention Center,
Room 25A-C(Upper Level) |
|
Ventilation Defect Burden Quantified byTechnegas SPECT and
Xe MRI Predicts Lung Cancer Resection Outcomes |
May 21, 2024 9:15 AM - 11:15 AM |
420 |
Session C29San Diego Convention Center,
Room 25A-C(Upper Level) |
|
Rapid and Persistent 6-week Responseto ICS/LABA/LAMA in
Mild-moderate Asthma |
May 21, 2024 11:30 AM - 1:15 PM |
P690 |
Session C71San Diego Convention Center,
Area F (Hall A-B2,Ground Level) |
|
Evaluation of Xenon Gas Phase and Dissolved Phase Delays
Using Dynamic 129Xe-hyperpolarized MRI in Pre-clinical Thoracic
Insufficiency Syndrome Model |
May 21, 2024 11:30 AM - 1:15 PM |
P156 |
Session C73San Diego Convention Center,
Area F (Hall A-B2,Ground Level) |
|
Xe MRI Reveals Regional Gas-exchange Abnormalities in
Cystic Fibrosis Lung Disease |
May 21, 2024 11:30 AM - 1:15 PM |
P174 |
Session C74San Diego Convention Center,
Area F (Hall A-B2,Ground Level) |
|
Quantitative Characterization of Regional Ventilation and
Perfusion in Patients With Persistent COVID-19 Symptoms Using
Hyperpolarized Xe MRI and Dual Energy CT |
May 21, 2024 11:30 AM - 1:15 PM |
P186 |
Session C75San Diego Convention Center,
Area F (Hall A-B2,Ground Level) |
|
The EXPLAIN (Hyperpolarised Xenon Magnetic Resonance
Pulmonary Imaging in Patients With Long-COVID) Study: The Primary
Outcome |
May 21, 2024 11:30 AM - 1:15 PM |
P195 |
Session C75San Diego Convention Center,
Area F (Hall A-B2,Ground Level) |
|
Same-day and Six-week Repeatability of Hyperpolarized Xe
MRI Measures in Patients With Pulmonary Arterial
Hypertension |
May 22, 2024 11:00 AM - 1:00 PM |
306 |
Session D109San Diego Convention Center,
Room 28C-E(Upper Level) |
Contact Information:
Polarean:Chuck OsborneChief Financial Officer+1 (919) 206-7900,
ext. 117cosborne@polarean.com
Polarean Investors:Anna Dunphy / Phillip Marriage+44 (0)20 7933
8780polarean@wallbrookpr.com
Polarean Media Contact:Alexis Opp+1 (919)
206-7900aopp@polarean.com
General inquiries: info@polarean.comFollow Polarean on LinkedIn
here
Polarean:
Chuck Osborne
Chief Financial Officer
+1 (919) 206-7900, ext. 117
cosborne@polarean.com
Polarean Investors:
Anna Dunphy / Phillip Marriage
+44 (0)20 7933 8780
polarean@wallbrookpr.com
Polarean Media Contact:
Alexis Opp
+1 (919) 206-7900
aopp@polarean.com
General inquiries: info@polarean.com
Polarean Imaging (LSE:POLX)
過去 株価チャート
から 1 2025 まで 2 2025
Polarean Imaging (LSE:POLX)
過去 株価チャート
から 2 2024 まで 2 2025
